Business Context and Reporting Period
This Form 8-K filing by Sunshine Heart, Inc. (not Nuwellis, Inc.) reports a material definitive agreement entered into on July 20, 2016. The report was filed on July 22, 2016. The company is a Delaware corporation focused on developing therapies, as indicated by references to clinical trials and regulatory filings in the forward-looking statements section.
Key Financial Metrics and Transaction Details
The filing details a capital raise consisting of a Registered Direct Offering and a concurrent Private Placement:
- Securities Issued: 3,468 shares of Series B Convertible Preferred Stock at $1,000 per share.
- Warrants Issued: Warrants to purchase an aggregate of 3,689,361 shares of common stock.
- Warrant Exercise Price: $0.94 per share.
- Expected Net Proceeds: Approximately $3.2 million after deducting placement agent fees and estimated expenses.
- Use of Proceeds: Working capital and general corporate purposes.
- Placement Agent Fees: 6% of aggregate gross proceeds in cash plus a warrant equal to 6% of the shares sold to investors.
The filing does not provide specific revenue, profit, cash flow, margin, or debt figures for the reporting period.
Material Changes and Transaction Terms
The primary material change is the execution of the Securities Purchase Agreement. Key terms include:
- Conversion: Preferred Stock is non-voting and convertible into common stock at $0.94 per share.
- Beneficial Ownership Limitation: Holders cannot exercise conversion or warrants if it results in beneficial ownership exceeding 4.99% (increasable to 9.99% with 61 days' notice).
- Lock-up: The company agreed not to issue or announce common stock or equivalents for 60 days from the agreement date.
- Participation Rights: Purchasers have the right to participate in up to 50% of any subsequent financing within 12 months on the same terms.
- Warrant Terms: Investor warrants are exercisable starting six months after issuance for 36 months. The Placement Agent warrant is exercisable immediately for five years.
Guidance, Outlook, and Risks
Management intends to use the proceeds for working capital and general corporate purposes. The filing contains extensive forward-looking statements regarding clinical study designs, trial timelines, regulatory approvals, and product commercialization. Management explicitly states that actual results may differ materially from expectations due to risks such as regulatory rejection, inability to raise further funds, and competitive product offerings. The company disclaims any obligation to update these forward-looking statements.
Important Facts for Investor Verification
- Verify the closing date of the transaction, expected to be July 26, 2016, subject to customary conditions.
- Confirm the exact number of shares outstanding to calculate the dilution impact of the 3,689,361 warrant shares and the convertible preferred stock.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and adjustment mechanisms for the warrant exercise price.
- Monitor the company's cash runway given the stated need for working capital and the risks associated with future fundraising.
- Check for any subsequent filings regarding the "Subsequent Financing" participation rights granted to the purchasers.